Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $28.07M rose 177.8% year over year, ahead of the +90.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 20.2% from the prior quarter. Over 3 fiscal years it compounded at +41.6% a year.
Context
- Selling, general & admin amounted to 654.3% of revenue in FY2025, up 257.0 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $194.3M (+126.6%) for the fiscal year ending Dec 2026, a step up from the +113.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $28.07M-20.2% QoQ
- Last fiscal yearDec 2025
- $85.76M+113.9% YoY
- LTMMar 2026
- $63.26M+90.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 85.76M USD
- Year-over-year change
- +113.9%
- 4-year CAGR
- +38.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.76M | +113.9% |
| FY2024 | 2024-12-31 | 40.1M | +15.4% |
| FY2023 | 2023-12-31 | 34.75M | +15.0% |
| FY2022 | 2022-12-31 | 30.22M | +28.7% |
| FY2021 | 2021-12-31 | 23.47M | — |
Selling, General & Admin vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +90.6% is the highest of 10, against a peer median of -15.6%.
- Selling, general & admin amounts to 360.3% of revenue for TNXP, versus a peer median of 1952.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $63.26M USD | +90.6% | +41.6% | 360.3% | |
| LTM Mar 2026 | $42.34M USD | -49.3% | -18.0% | 670.4% | |
| LTM Mar 2026 | $35.34M USD | -27.5% | -17.7% | 3080.9% | |
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $25.06M USD | -19.7% | +4.0% | — | |
| LTM Mar 2026 | $24.19M USD | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $16.54M USD | -15.6% | +10.2% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $10.95M USD | -28.8% | +14.3% | — | |
| Peer median (excluding TNXP) | — | -15.6% | +3.4% | 1952.5% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.